Provided in the present Methods of use of anti LGR5, for example, to treat a disease related to Hedgehog which includes basal cell carcinoma. Claim 1: a method of treating a Hedgehog related disease in an individual comprising administering to the individual an effective amount of an Antibody anti LGR5.The Method of claim 18: According to any one of claims 1 to 17, where the LGR5 Antibody (AB has the Formula - L - d) u209a, where: (a) AB is the LGR5 Antibody； (b) l is a Linker； (c) D is a drug selected from a maitansinoide, auristatin, Cali Cheamicina, a pirrolobenzodiazepina and a Derivative of nemorrubicina； and (d) P varies from 1 - 8.Claim 20: The Method according to claim 18, where d is the formula (1) and where R u00b2 and r u2076 are each r u00b3 Methyl, Isopropyl and r u2074 are each, r u2075 is H, r u2077 is SEC butyl, each r u2078 selected, independently of ch u2083, or - ch u2083, oh and H； r u2079 is h； and R u00b9 u2078 is - C (- C (r u2078) u2082 r u2078) u2082 - aryl.Claim 22: The Method according to claim 18, where d is a pirrolobenzodiazepina of formula (2) where the dotted lines indicate the presence of a double Bond between c u00b9 Optional and C u00b2 or C u00b2 and c u00b3； R u00b2 is selected, independent of H, Oh, o =, =. Ch u2082, CN, r, or C = = CH - RD (RD) u2082, SO u2082 - or - R, and Cor, and optionally also selected Halo or Dihalo,Where Rd is selected independently of R, co u2082r, Cor, Cho, and co u2082h Halo； r u2076 and r u2079 are selected independently, h, r, or, Oh, sh, nh u2082, NHR, NRR, no u2082, me u2083sn and Halo； r u2077 selected, so independent of H, r, or, Oh, sh, nh u2082, NHR, NRR, no u2082, I u2083sn and Halo； Q is selected independently of o, S, and R is H or r u00b9 u00b9 NH； or, when q is so u2083m, or,Where M is a metal cation； R and R are each, independently, c u2081 u208b u2088 optionally substituted alkyl groups, heterociclilo c u2083 u208b u2088 and aryl c u2085 u208b u2082 u2080 and optionally in conjunc
